Literature DB >> 31144310

Toll-like receptors: A pathway alluding to cancer control.

Ana Patricia Ayala-Cuellar1, Jaejin Cho2, Kyung-Chul Choi1,3.   

Abstract

Toll-like receptors (TLRs) are usually expressed on immune cells such as macrophages, dendritic cells, mast cells, as well as on eosinophils and some epithelial cells. They play a central role in the recognition of harmful molecules that belong to invading microorganisms or internal damaged tissues, which lead to inflammation. Among the hallmarks of cancer, there is immune evasion and inflammation. Summing this with the discovery that a majority of cancers also seem to express TLRs, made researchers realize these receptors might also be linked with cancer progression. This review will cover some of the effects of TLR engagement in cancer cells that might induce the promotion or inhibition of cancer with mechanisms involved. The differences of TLR expression in cancer progression and its possible relation with patient prognosis, TLR genetic disorders found in cancer, and new strategies to cancer therapy will be discussed to target TLRs in cancer cells.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Toll-like receptors; cancer immunology; cancer progression; innate immunity

Mesh:

Substances:

Year:  2019        PMID: 31144310     DOI: 10.1002/jcp.28879

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  4 in total

1.  ACK1 Contributes to the Pathogenesis of Inflammation and Autoimmunity by Promoting the Activation of TLR Signaling Pathways.

Authors:  Lina Jing; Xin Zhang; Dong Liu; Yonghong Yang; Huabao Xiong; Guanjun Dong
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

2.  Association between serum soluble Toll-like receptor 2 and 4 and the risk of breast cancer.

Authors:  Ghada El-Kharashy; Ahmed Gowily; Tarek Okda; Maha Houssen
Journal:  Mol Clin Oncol       Date:  2020-12-24

3.  Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8+ T cell cytotoxicity in patients with gastric cancer.

Authors:  Junli Xu; Rongya Guo; Jing Jia; Yun He; Shuixiang He
Journal:  BMC Immunol       Date:  2021-10-07       Impact factor: 3.615

4.  Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis.

Authors:  Jun-Lin Lu; Qi-Dong Xia; Yi Sun; Yang Xun; Heng-Long Hu; Chen-Qian Liu; Jian-Xuan Sun; Jin-Zhou Xu; Jia Hu; Shao-Gang Wang
Journal:  Front Cell Dev Biol       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.